BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company developing novel immunotherapies, has a key clinical trial milestone this year as it advances potential treatments for patients with metastatic breast cancer facing urgent medical needs.
Breast cancer is the most common cancer in women in the United States, with more than 40,000 deaths per year in the United States, according to the latest data from the American Cancer Society.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com